CONCERTO clinical trial is seeking participants to evaluate the new investigational SING IMT Long-time members of our AMD community may remember FDA approval in 2010 of a device from Samsara Vision (formerly VisionCare, Inc.) called the Implantable Miniature Telescope (IMT). This device is a tiny telescope which provides precision images, magnification of up to 3 times, [Read More]
News
Seeing Red
What makes us angry? As visually impaired and blind senior adults, we often find ourselves metaphorically seeing red when confronted by life without our most dominant sense. We are angered by our loss of independence, our inability to fight injustices, and by the ignorance or indifference of others. Since most of us hale from the [Read More]
BYOOVIZ™ Launches in the U.S.
Biogen Inc. and Samsung Bioepis Co., Ltd. has announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar of LUCENTIS® (ranibizumab) has been launched in the U.S. and will be commercially available on July 1, 2022. The list price will be $1,130 per injection, which is 40% lower than the current list price of LUCENTIS. The FDA approved BYOOVIZ [Read More]
Does VUITY™ Treat AMD?
A new drug called VUITY™ (pilocarpine hydrochloride ophthalmic solution) has recently gained attention as an eye drop that can improve near (close up) vision in individuals over 40. It does not, however, change the condition of the retina. The drug, made by Allergan, works as advertised, but it should not be expected to treat age-related [Read More]
Long-awaited Faricimab for wet AMD and DME approved
The FDA has approved Genentech’s Vabysmo (first announced here as faricimab), the only injectable eye medicine approved simultaneously in the U.S. for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Vabysmo will be administered using flexible dosing regimens based on patient need. The medication targets and inhibits two disease pathways by neutralizing angiopoietin-2 [Read More]